TXINNO Bioscience
Have updates for this profile? Please contribute data
= Subscriber Access Only
You are viewing a preview of this profile. Request a Preqin Pro demo for full access to all profiles and underlying data.
With Preqin Pro, you gain an unobstructed view of all alternative asset class activity across institutional investors, fund managers, funds, portfolio companies, deals, exits, and service providers.
TXINNO Bioscience - overview
Established
2020
Location
Yongin, -, South Korea
Primary Industry
Pharmaceuticals
About
Founded in 2020 and based in Yongin, South Korea, TXINNO Bioscience operates as a researcher and manufacturer of molecular immuno-oncology drugs. The company utilizes artificial intelligence technology to develop certain enzyme-inhibiting drugs and therapeutics that allow the activation of innate immunity in cancer patients. In March 2023,TXINNO Bioscience raised KRW 2 billion in venture funding from new investors Korea Venture Investment Corporation and Hyundai Pharm. As of 2023, the company is led by its CEO Park Chan-sun.
The company will use the March funding to accelerate phase 1 clinical research of its core pipeline, ENPP1 inhibitor 'TXN10128'.
Current Investors
Schmidt, Korea Investment Partners, DSC Investment
Primary Industry
Pharmaceuticals
Sub Industries
Molecular Science, Genetics & Gene Therapy, Biopharmaceuticals, Oncology/Cancer Treatment, Pharmaceutical Research & Development
Website
www.txinno.com
Verticals
Artificial Intelligence, HealthTech, Manufacturing
Company Stage
Series B
Total Amount Raised
Subscriber access only
TXINNO Bioscience - employee data
Time to go Pro
Get Preqin Pro for unrestricted access to 600,000+ detailed profiles on fund managers, investors, funds, companies, and other alternative asset players. Unlock exclusive data on future plans, company financials, fundraising history, track records, and more.